Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136632

Published: 2020

Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Blood (2019) 134 (Supplement_1): 2950.

https://doi.org/10.1182/blood-2019-126035

Published: 2019

Journal Articles

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Massimiliano Bonifacio, MD, Patrizia Bonadonna, MD, Hanneke Oude Elberink, MD, Björn van Anrooij, MD, Aleksandra Górska, MD, Magdalena Lange, MD, Emir Hadzijusufovic, DVM, Luigi Scaffidi, Ilaria Tanasi, MD, Cecelia Perkins, Virginia Valeria Ferretti, Anja Illerhaus, PhD, Thilo Jakob, MD, Roberta Parente, MD, Mohamad Jawhar, MD, Francesca Caroppo, MD, Alexander Zink, MD, Alex Kilbertus, MD, Akif Selim Yavuz, MD, Michael Doubek, MD PhD, Hans Hagglund, MD PhD, Jens P. Panse, MD, Vito Sabato, MD PhD, Elisabeth Aberer, MD, Nadja Jaekel, MD, Peter Vandenberghe, MD PhD, David Fuchs, MD, Knut Brockow, MD, Anna Belloni Fortina, MD, Andreas Reiter, MD, Massimo Triggiani, MD, Khalid Shoumariyeh, MD, Karin Hartmann, MD, Chiara Elena, Olivier Hermine, MD PhD, Jason Gotlib, MD, Marek Niedoszytko, MD, Hanneke Kluin-Nelemans, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Roberta Zanotti, MD

Blood (2017) 130 (Supplement 1): 4200.

https://doi.org/10.1182/blood.V130.Suppl_1.4200.4200

Published: 2017

Journal Articles

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Blood (2017) 130 (Supplement 1): 1650.

https://doi.org/10.1182/blood.V130.Suppl_1.1650.1650

Published: 2017

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Jason Gotlib, MD MS, Hanneke C. Kluin-Nelemans, MD PhD, Tracy I. George, MD, Cem Akin, MD PhD, Karl Sotlar, MD, Olivier Hermine, MD PhD, Farrukh Awan, MD MS, Elizabeth O Hexner, MD, Michael Mauro, MD, David Sternberg, MD PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Eric Stanek, PharmD, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2014) 124 (21): 636.

https://doi.org/10.1182/blood.V124.21.636.636

Published: 2014

Journal Articles

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

Sabine Cerny-Reiterer, D.V.M, Anja Rabenhorst, Msc, Ph.D., Gabriele Stefanzl, Msc, Susanne Herndlhofer, Katharina Blatt, MSc, Ph.D., Gregor Hoermann, M.D., Ph.D., Leonhard Muellauer, M.D., Sigrid Baumgartner, M.D., Christine Beham-Schmid, M.D., Wolfgang R Sperr, M.D., Werner Linkesch, M.D., Christine Mannhalter, M.D., Michel Arock, PharmD, Ph.D, Karin Hartmann, M.D., Peter Valent

Blood (2013) 122 (21): 3988.

https://doi.org/10.1182/blood.V122.21.3988.3988

Published: 2013

Journal Articles

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Jason Gotlib, MD, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, John Coombs, PharmD, MBA, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2013) 122 (21): 106.

https://doi.org/10.1182/blood.V122.21.106.106

Published: 2013

Journal Articles

Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation

Katia De Filippo, Anne Dudeck, Mike Hasenberg, Emma Nye, Nico van Rooijen, Karin Hartmann, Matthias Gunzer, Axel Roers, Nancy Hogg

Blood (2013) 121 (24): 4930–4937.

https://doi.org/10.1182/blood-2013-02-486217

Published: 2013

Includes: Supplemental data

Journal Articles

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

Blood (2013) 121 (13): 2393–2401.

https://doi.org/10.1182/blood-2012-09-458521

Published: 2013

Includes: Supplemental data

Journal Articles

The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.

Juliana Schwaab, MD, Philipp Erben, MD, Hans-Peter Horny, MD, Martina Teichmann, MD, Georgia Metzgeroth, MD, Thomas Ernst, MD, Karl Sotlar, MD, Martin C Mueller, MD, Alexander Marx, MD, Karin Hartmann, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD, Wolf Karsten Hofmann, MD, PhD, Andreas Reiter, MD

Blood (2012) 120 (21): 2859.

https://doi.org/10.1182/blood.V120.21.2859.2859

Published: 2012

Journal Articles

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Jason Gotlib, MD, MS, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, MD, PhD, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael J. Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2012) 120 (21): 799.

https://doi.org/10.1182/blood.V120.21.799.799

Published: 2012

Journal Articles

Mast cells play a protumorigenic role in primary cutaneous lymphoma

Anja Rabenhorst, Max Schlaak, Lukas C. Heukamp, Anja Förster, Sebastian Theurich, Michael von Bergwelt-Baildon, Reinhard Büttner, Peter Kurschat, Cornelia Mauch, Axel Roers, Karin Hartmann

Blood (2012) 120 (10): 2042–2054.

https://doi.org/10.1182/blood-2012-03-415638

Published: 2012

Includes: Supplemental data

Journal Articles

Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit

Alexander Gerbaulet, Claudia Wickenhauser, Julia Scholten, Katrin Peschke, Sebastian Drube, Hans-Peter Horny, Thomas Kamradt, Ronald Naumann, Werner Müller, Thomas Krieg, Claudia Waskow, Karin Hartmann, Axel Roers

Blood (2011) 117 (6): 2012–2021.

https://doi.org/10.1182/blood-2008-11-189605

Published: 2011

Includes: Supplemental data

Journal Articles

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)

Peter Valent, Michel Arock, Cem Akin, Wolfgang R. Sperr, Andreas Reiter, Karl Sotlar, Karin Hartmann, Tracy I. George, Knut Brockow, Hanneke C. Kluin-Nelemans, Jason Gotlib, Dean D. Metcalfe, Hans-Peter Horny

Blood (2010) 116 (5): 850–851.

https://doi.org/10.1182/blood-2010-05-285270

Published: 2010

Journal Articles

The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells

Sebastian Drube, Sylvia Heink, Sabine Walter, Tobias Löhn, Mandy Grusser, Alexander Gerbaulet, Luciana Berod, Julia Schons, Anne Dudeck, Jenny Freitag, Stefan Grotha, Daniela Reich, Olga Rudeschko, Johannes Norgauer, Karin Hartmann, Axel Roers, Thomas Kamradt

Blood (2010) 115 (19): 3899–3906.

https://doi.org/10.1182/blood-2009-10-247411

Published: 2010

Includes: Supplemental data

Journal Articles

C3a and C5a Stimulate Chemotaxis of Human Mast Cells

Karin Hartmann, Beate M. Henz, Sabine Krüger-Krasagakes, Jörg Köhl, Reinhard Burger, Sven Guhl, Ingo Haase, Undine Lippert, Torsten Zuberbier

Blood (1997) 89 (8): 2863–2870.

https://doi.org/10.1182/blood.V89.8.2863

Published: 1997

NARROW

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Mast cells play a protumorigenic role in primary cutaneous lymphoma

Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)

The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells

C3a and C5a Stimulate Chemotaxis of Human Mast Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only